Memorial Hermann–Texas Medical Center

Merrill named Chair, Peri, Hemmelgarn and Keifer join Board of Directors for International Children's Hospitals' Patient Safety Collaborative

Retrieved on: 
Wednesday, December 20, 2023

COLUMBUS, Ohio, Dec. 20, 2023 /PRNewswire/ -- The international children's hospital patient and employee safety network, Children's Hospitals' Solutions for Patient Safety (SPS) , has named Rick Merrill, president and CEO of Cook Children's Health Care System, as its newest board chair.

Key Points: 
  • COLUMBUS, Ohio, Dec. 20, 2023 /PRNewswire/ -- The international children's hospital patient and employee safety network, Children's Hospitals' Solutions for Patient Safety (SPS) , has named Rick Merrill, president and CEO of Cook Children's Health Care System, as its newest board chair.
  • SPS efforts have spared more than 25,000 children from serious harm and led to estimated savings of $533+ million.
  • Merrill will assume the role of chair previously held by Marcy Doderer, president and CEO of Arkansas Children's.
  • She was an adjunct professor at the University of Illinois Chicago for ten years teaching in their master's program for patient safety.

Regener-Eyes CEO C. Randall Harrell MD Recognized Among World's Top 2% of ALL Scientists by Stanford University and Elsevier

Retrieved on: 
Friday, October 20, 2023

TAMPA, Fla., Oct. 20, 2023 /PRNewswire/ -- Regener-Eyes®, led C. Randall Harrell, MD, the CEO and Chief Scientist, is proud to announce his inclusion in the top 2% of all scientists worldwide, as recognized by Stanford University and Elsevier.

Key Points: 
  • TAMPA, Fla., Oct. 20, 2023 /PRNewswire/ -- Regener-Eyes®, led C. Randall Harrell, MD, the CEO and Chief Scientist, is proud to announce his inclusion in the top 2% of all scientists worldwide, as recognized by Stanford University and Elsevier.
  • This prestigious acknowledgment, presented in a global database featuring elite scientists, is a testament to a lifetime of dedication and excellence.
  • Dr. C. Randall Harrell's illustrious career commenced at Emory University, where he contributed to the Department of Tumor Biology and Clinical Immunology.
  • Dr. Harrell says," This remarkable achievement reflects the collective success of our team, and I extend my heartfelt congratulations to all involved."

Beachside continues to thrive, attracting hundreds of visitors and new residents to Palacios

Retrieved on: 
Thursday, September 28, 2023

PALACIOS, Texas, Sept. 28, 2023 /PRNewswire-PRWeb/ -- Beachside, the idyllic waterfront community nestled along the Texas Coast in Matagorda County, provides a significant positive impact to the City of Palacios. Beachside has become a sought-after destination, resulting in remarkable growth and boosting economic activity in the region.

Key Points: 
  • PALACIOS, Texas, Sept. 28, 2023 /PRNewswire-PRWeb/ -- Beachside, the idyllic waterfront community nestled along the Texas Coast in Matagorda County, provides a significant positive impact to the City of Palacios.
  • Beachside has become a sought-after destination, resulting in remarkable growth and boosting economic activity in the region.
  • Beachside offers a unique blend of serenity and recreational opportunities, making it a perfect place to live, work, and play.
  • As Beachside continues to grow and welcome new residents and visitors, the future looks bright for both the community and the City of Palacios.

Texas Children's Pavilion for Women Announces Opening of New Medical Tower

Retrieved on: 
Monday, August 7, 2023

HOUSTON, Aug. 7, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the newest medical tower, Pavilion for Women Tower II, has opened for patient activity. As the second phase of the $245 million Texas Children's Pavilion for Women's expansion within the Texas Medical Center nears completion, the new tower connected to the Pavilion for Women via a recently constructed sky bridge houses women's services outpatient clinics, including The Women's Specialists of Houston, Partners in OB/GYN Care, and Women's Physical Therapy.

Key Points: 
  • HOUSTON, Aug. 7, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the newest medical tower, Pavilion for Women Tower II, has opened for patient activity.
  • Since opening its doors over a decade ago, the Pavilion for Women has seen rapid growth in the volume of patients seeking labor and delivery services, and the next step of this expansion includes increasing the number of hospital beds in the Texas Children's Pavilion for Women.
  • "I am so proud of everything we've done together and I'm beyond grateful and excited for the continuous growth of Texas Children's Pavilion for Women."
  • Texas Children's is consistently ranked among the best children's hospitals nationally by U.S. News & World Report, and first in Texas.

Memorial Hermann Hospitals Recognized by U.S. News & World Report

Retrieved on: 
Tuesday, August 1, 2023

HOUSTON, Aug. 1, 2023 /PRNewswire/ -- TIRR Memorial Hermann Hospital has been named a national leader in rehabilitative care and the  best rehabilitation hospital in Texas for 2023-2024, according to U.S. News & World Report.

Key Points: 
  • "As innovative leaders in clinical care, research, education and advocacy, TIRR Memorial Hermann is honored to be recognized by physicians and U.S. News and World Report as a national leader for the 34th consecutive year," said Rhonda Abbott, senior vice president and CEO of TIRR Memorial Hermann.
  • Other Memorial Hermann recognitions include:
    Children's Memorial Hermann Hospital was ranked as the No.
  • This campus includes Memorial Hermann | Rockets Orthopedic Hospital, Memorial Hermann Cypress Hospital and Children's Memorial Hermann Hospital.
  • This campus includes Memorial Hermann Greater Heights, Memorial Hermann The Woodlands Medical Center, Memorial Hermann Pearland Hospital, Memorial Hermann Southeast Hospital and Memorial Hermann Southwest Hospital.

New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Retrieved on: 
Monday, June 26, 2023

SPRING HOUSE, Pa., June 26, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) hemolytic disease of the fetus and newborn (HDFN).1 A statistically significant (54 percent [n=7/13]) proportion of participants who received nipocalimab achieved the primary endpoint of a live birth at or after gestational age of 32 weeks without intrauterine transfusions (IUTs)1,a compared to the historic reference point of 10 percent, which was derived from published and unpublished data.2-5,b Among the seven participants who achieved the primary endpoint, the median gestational age at delivery was 37 and 1/7 weeks.6 This study demonstrates the potential for nipocalimab to help address the underlying disease mechanism of EOS HDFN.1 If approved, nipocalimab would be the first anti-neonatal Fc receptor (FcRn) treatment and the first approved non-surgical intervention for pregnancies at high risk of HDFN in the U.S.7 These data will be presented for the first time at the Fetal Medicine Foundation World Congress in Valencia, Spain on June 26, 2023.1 Janssen is planning a pivotal Phase 3 trial for nipocalimab in pregnancies at risk for severe HDFN.

Key Points: 
  • "There is a significant unmet need to help address the serious and life-threatening health consequences of HDFN.
  • "These Phase 2 UNITY data in high-risk pregnancies demonstrated the important role that nipocalimab, an FcRn blocking antibody, may play in preventing the transfer of maternal alloantibodies through the placenta, thereby offering a potential treatment option for this devastating disease."
  • A conservative benchmark of 10 percent of patients not requiring an IUT was chosen to account for uncertainties in the accuracy and representation of the underlying data.2
    d.  Dr. Kenneth Moise is a paid consultant for Janssen.
  • He has not been compensated for any media work.

Acasti Announces Appointment of New Scientific Advisory Board Members

Retrieved on: 
Thursday, June 22, 2023

LAVAL, QC, June 22, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced the appointment of W. Taylor Kimberly, MD, PhD, Alejandro A. Rabinstein, MD and Sherry H-Y. Chou, MD to its Scientific Advisory Board.

Key Points: 
  • Chou, MD to its Scientific Advisory Board.
  • "We are extremely pleased to add eminent physicians with a deep understanding of aSAH and neurocritical care to the Acasti Scientific Advisory Board," commented Prashant Kohli, CEO of Acasti.
  • Kimberly, Rabinstein and Chou will offer unmatched insight into this indication."
  • "Acasti's Scientific Advisory Board now has a perfect blend of clinical expertise including neurosurgery and neurocritical care from the leading academic medical centers in the country," Kohli concluded.

Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma

Retrieved on: 
Thursday, June 1, 2023

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma.

Key Points: 
  • Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma.
  • MATRICS-1 is supported in part by MTEC (Medical Technology Enterprise Consortium) in partnership with the Department of Defense, and funding from Memorial Hermann Foundation.
  • MultiStem’s unique mechanism of action has the potential to address the often fatal complications that occur following a severe traumatic event.
  • The MATRICS-1 double-blind, placebo-controlled Phase 2 study is evaluating the safety and effectiveness of MultiStem for the prevention and early treatment of complications after severe traumatic injury.

TEXAS CHILDREN'S ANNOUNCES SEARCH FOR NEW PRESIDENT

Retrieved on: 
Friday, May 5, 2023

HOUSTON , May 5, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce its search for a new President of the organization. The new President will report to Mark A. Wallace, who will continue to serve as Chief Executive Officer.

Key Points: 
  • Mark A. Wallace remains Chief Executive Officer
    HOUSTON , May 5, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce its search for a new President of the organization.
  • Texas Children's stated the search for the organization's next President would be a thoughtful, strategic and progressive process with a flexible timeline.
  • "Mark's significance to Texas Children's and the Texas Medical Center is beyond compare, and we are grateful to have Mark be a part of this process as we begin our search."
  • Wallace has served as President & CEO of Texas Children's for over three decades and has served in a leadership role in the Texas Medical Center for 45 years.

Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial

Retrieved on: 
Monday, April 24, 2023

The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.

Key Points: 
  • The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • A live question and answer session will follow the formal presentations.
  • Todd M Bertoch, MD, is a diplomate of the American Board of Anesthesiology.
  • After receiving his Fellowship in the Faculty of Anesthesiologists in South Africa, he relocated to the Texas Medical Center in Houston.